A model of stimulated bone resorption was developed using a synthetic retinoid in thyroparathyroidectomized rats. The retinoid induced an increase in bone resorption and in the number of vertebral subperiosteal osteoclasts. The resulting increase in plasma Ca could be used as an easily measured index of bone resorption. Three bisphosphonates produced a dose-related prevention and reversal of retinoid-induced hypercalcemia. Their potencies were similar to those previously obtained by histomorphometry. Irradiation (600 rad) of the rats prevented hypercalcemia but failed to reverse it, showing that proliferation of osteoclast precursor cells was important in inducing, but not in maintaining, bone resorption. Calcitonin produced similar effects on calcemia and prevented the increase in osteoclast number but failed to reverse the increase, suggesting that it inhibited precursor proliferation. This model represents a new tool to study mechanisms of bone resorption and the action of inhibitors in vivo.
Introduction
Bone resorption by osteoclasts is a process which is tightly controlled by a number of circulating and local factors (1-3). Regulation can occur at different levels, namely by altering the activity of osteoclasts present in bone or by influencing the generation of new osteoclasts from precursor cells. Osteoclasts are thought to originate from stem cells in the bone marrow under the influence of hemopoietic growth factors. Multinucleated osteoclasts are then generated by fusion of precursor cells (4, 5) . The activation of osteoclasts can be studied using the acute hypercalcemic effect of PTH in parathyroidectomized rats. This system has been successfully used to study the inhibitory effect ofbisphosphonates on bone resorption (6) . In contrast, an animal model of bone resorption in which this process is altered mainly by a recruitment of new osteoclasts and which allows to monitor this process by an easily measured biochemical parameter such as plasma calcium has, to our knowledge, not been reported.
Because it has long been known that excess vitamin A leads to an increase of osteoclastic bone resorption and of the number of osteoclasts (7-9), we have studied whether a synthetic vitamin A derivative (retinoid) shown in Fig. 1 might be used to develop such a model. The arotinoid used is one ofthe most potent retinoids known in terms of vitamin A activity (10, 1 1) .
In this paper we demonstrate that the retinoid is a potent stimulator of bone resorption in the thyroparathyroidectomized (TPTX)' rat and that the increase in bone resorption involves the generation of new osteoclasts. The changes in bone resorption can be easily monitored by measuring plasma Ca. This system proved to be suitable to study the effect of inhibitors of bone resorption and to differentiate between their effects on osteoclast activity and on proliferation of precursors.
Methods
Except for the balance and 45Ca kinetics study, male Wistar rats weighing 150-180 g from our breeding colony were used. The animals were thyroparathyroidectomized surgically under ether anesthesia and from then on received 1 gg thyroxin subcutaneously three times a week. The success of parathyroidectomy was tested by measuring plasma Ca 8 d after the operation. Rats with < 2 mM plasma Ca were considered TPTX. The TPTX rats were placed in single cages and pair-fed a commercial chow containing 1 g Ca/100 g, 0.75 g P/100 g, and 800 IU vitamin D3/kg (Kliba 331, Klingenthalmihle, Basel, Switzerland). Blood was taken either by retroorbital puncture, aortic puncture, or from the tip of the tail and collected in heparinized tubes. Plasma was then obtained by centrifugation.
The retinoid ethyl p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtyl]benzoate (Ro 13-6298, a gift from Hoffmann La Roche AG, Basel, Switzerland) ( Fig. 1) , was administered subcutaneously in 0.1 ml/rat of polyethylene glycol 300 with 10% ethanol. Control animals received the vehicle alone.
The bisphosphonates dichloromethylenebisphosphonate (Cl2-MBP), 3-amino-I -hydroxypropylidene-1, -bisphosphonate (AHPrBP) (both provided by Procter & Gamble Co., Cincinnati, OH), and 4- amino-l-hydroxybutylidene-l 1,-bisphosphonate (AHBuBP) (from Gentili S.p.A., Pisa, Italy) were dissolved in water, the pH was adjusted to 7.4, and NaCl was added to obtain isotonic solutions. The drugs were given subcutaneously in 2 ml/kg body wt.
Bovine parathyroid hormone (TCA powder, Sigma Chemical Co., St. Louis, MO) was injected subcutaneously in 0.2 ml/rat of0. 15 NaCl containing 0.01 M HCl, 1 mg/ml bovine serum albumin, and 0.16 M glutathion.
1. Abbreviations used in this paper: AHBuBP, 4-amino-l-hydroxybutylidene-l 1,-bisphosphonate; AHPrBP, 3-amino-l-hydroxypropylidene-l,1-bisphosphonate; C12MBP, dichloromethylenebisphosphonate; CT, calcitonin; 25(OH)D, 25- Salmon calcitonin (CT) (Calcitonin-Sandoz, 100 Medical Research Center units/ml; Sandoz AG, Basel, Switzerland) was diluted in 0.1 M Na acetate with 1% bovine serum albumin and injected subcutaneously in a volume of 1 ml/kg body wt.
Balance and 'Ca kinetics. This method was originally described by Aubert and Milhaud (12) and later modified as described earlier (13, 14) . Weaning female Wistar rats from our own breeding colony were fed a commercial chow (Kliba 331) containing 1.0 g/l00 mg Ca, 0.75% P, and 800 IU vitamin D3/kg. At The measurements of nonradioactive Ca allowed the determination of (a) intake of Ca, (b) net intestinal Ca absorption, and (c) Ca retention in the body. The latter is assumed to be entirely due to skeletal retention. The measurements of 45Ca allowed, using a model with two compartments, the calculation of (a) bone formation defined as the amount of Ca which leaves the first compartment irreversibly over the time period measured and is not accounted for by Ca appearing in urine and the feces, (b) bone resorption calculated as the difference between the rates of bone formation and the Ca retention in the body, and (c) urinary Ca calculated by dividing the total urinary '"Ca by the integral of plasma specific radioactivity. All fluxes are expressed as millimoles per day.
Determination of bone mineral content. Tibiae and spines were removed and freed from remaining soft tissue by Dermestid beetles (Dermestes maculatus) as described previously (15) . The 
Results
Balance and 5Ca-kinetics. Preliminary experiments had shown that the retinoid increased plasma Ca in TPTX rats. Although these results suggested that the compound might stimulate bone resorption, hypercalcemia could also have been due to the action of the retinoid on Ca metabolism at another site. A balance and '"Ca-kinetics study was therefore performed to identify the sites of action of the compound on Ca metabolism. Because the retinoid effect appeared to require a few days to develop the Ca balance and '"Ca kinetics measurements were started after 6 d of retinoid administration.
The main findings are presented in Fig. 2 , A and B. Fig. 2 A demonstrates that the retinoid produced a conspicuous increase of Ca release from bone, i.e., bone resorption, whereas Ca entry into bone, i.e., bone formation, was unaffected. Plasma Ca was significantly increased at the highest dose level tested. Plasma phosphate was unchanged (data not shown). As shown in Fig. 2 Therefore, it appeared that the retinoid-induced decrease in intestinal Ca absorption might well be explained by a decrease in plasma 1,25(OH)2D. In contrast, the stimulation of bone resorption was unlikely to be related to a difference in vitamin D metabolism.
Retinoid-induced hypercalcemia in TPTX rats. In view of the likely possibility that the observed increase in plasma Ca in rats given the largest dose of retinoid was due to the increased Ca release from bone, we then investigated whether plasma Ca might be used as an easily measured biochemical parameter to monitor bone resorption in retinoid-treated TPTX rats. In a first step, the time course of the induction of hypercalcemia and the conditions to maintain it were studied. To produce a rapid increase in bone resorption, the maximal tolerated dosage was also determined.
A single injection of 100 ,gg of retinoid produced a progressive increase of plasma Ca that was detectable after 24 h and continued over 4 d. Signs of hypervitaminosis A appeared on the second day after retinoid administration. In subsequent experiments, the retinoid was given three times at 25 Mg/rat on three consecutive days (Fig. 4, A and B) . With this schedule, signs of general toxicity, namely a decreased food intake, conjunctivitis, and hair loss, did not appear until day 4, and the time course of the increase in plasma Ca was indistinguishable from that observed with a single injection of 100 Mg/rat. Plasma Ca reached a maximum on day 4 and then decreased to control values within 2-3 d. The level could be maintained or elevated by continuing retinoid administration, given either daily at a lower dose or intermittently. Fig. 4 B shows that one additional injection of retinoid given on day 4 at the same dose was able to maintain plasma Ca until day 6.
Effect ofretinoid treatment on bone mass in TPTX rats. To assess the extent ofbone destruction under the conditions used in the experiments of Fig. 4 , A and B, we used these treatment schedules to determine bone mass as assessed by measuring dry weight, defatted dry weight, ash weight, and Ca content in tibiae as well as vertebrae. As shown in Table II , no significant effect on bone mass could be detected 3 d after the onset of retinoid treatment. 6 d after beginning treatment, however, all parameters were lower than in the corresponding solventtreated animals, statistical significance being reached in all, with the exception of Ca content of the tibia.
These results confirm that retinoid treatment stimulated bone resorption. Moreover, they show that plasma Ca is a more sensitive parameter to evaluate this effect than mineral analysis of the bones.
Effect ofretinoid ofosteoclast number in TPTX rats. To test whether the retinoid induced bone resorption by activating (20) .
The drugs were given in two different situations. In the first we tested whether they could prevent the induction of hypercalcemia by the retinoid ("preventive" effect), and then whether they could reverse the hypercalcemia after it had been induced with retinoid ("curative" effect). The experimental protocols are shown in Fig. 5 .
As shown in Fig. 6 , all three bisphosphonates produced a dose-related inhibition of retinoid-induced hypercalcemia. The dose-response curves were almost identical in the preventive and the curative protocols. At the highest dose-levels tested, plasma Ca was in the range observed in untreated TPTX rats, indicating that the hypercalcemic effect of the retinoid was totally abolished. The dose-response curves were the same as those obtained previously in rats using histomorphometry (19). The radiomicrographs of Fig. 7 demonstrate that retinoid treatment resulted in a marked thinning of the cortical shaft of the head of the tibia, which, moreover, had an increased porosity (Fig. 7 B) . These changes were completely inhibited by all three bisphosphonates given at a dose that prevented retinoid-induced hypercalcemia (Fig. 7, C-E) .
Effect of irradiation on retinoid-induced hypercalcemia in TPTX rats. To assess whether the retinoid effect on recruitment involved the proliferation of precursor cells or only the formation of osteoclasts by fusion from postmitotic precursors, TPTX rats were irradiated with a dose known to abolish the proliferation ofbone marrow cells (16), and plasma Ca was measured to monitor the effect of retinoid treatment on bone resorption.
As shown in the left panel of Fig. 8 , irradiation of TPTX rats with 600 rad resulted in a complete abolition of retinoidinduced hypercalcemia, suggesting that proliferation of osteoclast precursors plays a central role in the induction of bone resorption by the retinoid. To ascertain that the irradiation did not act by inhibiting the osteoclasts already present, we assessed the hypercalcemic effect of PTH (6) . TPTX rats were irradiated and then immediately given 300 IU of PTH subcutaneously. Plasma Ca was measured before and 6 h after the administration of the hormone. In irradiated rats, the PTHinduced increase in plasma Ca was 0.47±0.08 mM (x±SEM, n = 4). This value was not significantly different from the increase of 0.62±0.08 mM observed in control TPTX rats. Therefore, osteoclasts present remained responsive to PTH after irradiation. Fig. 8 , right panel, shows that irradiation, in opposition to bisphosphonates, had no effect on retinoid-induced hypercalcemia once it had been induced. This lack of effect also shows that osteoclasts once formed are not influenced by irradiation, and suggests that in the conditions used to study the curative effect of bone resorption inhibitors, proliferation of osteoclast precursors plays no significant role in maintaining bone resorption at a high level.
Effect of CT on retinoid-induced hypercalcemia in TPTX rats. CT is known to be a potent specific physiological inhibitor of osteoclastic bone resorption. Therefore, the effect of this hormone on retinoid-induced hypercalcemia was studied using the preventive and curative protocols (Fig. 5) .
The effect of CT was assessed in two ways. First, plasma Ca was measured 24 h after the last injection of CT. This permitted to exclude the acute hypocalcemic effect of CT which lasts only a few hours. In addition, the acute hypocalcemic effect was also assessed by measuring plasma Ca 2 h after the injection of CT.
As shown in Fig. 9 , CT given simultaneously with retinoid prevented the increase of plasma Ca as assessed 24 h after the last injections of CT and retinoid. The same dose of CT failed, however, to reverse retinoid-induced hypercalcemia once it had been induced. Similar results were obtained at a lower dose of 4 IU/kg in both protocols. These results are strikingly similar to those obtained with irradiation. Thus, it appears that CT prevented the recruitment of osteoclast precursors by retinoid.
In identical experiments, osteoclast numbers were then determined in groups sacrificed either at the end of the preventive (day 3) or the curative protocol (day 6). These results are shown in Table IV . In the preventive protocol, osteoclast numbers in retinoid-plus-CT-treated animals were about half of those found in rats given retinoid alone. Retinoid-induced hypercalcemia was abolished as in the previous experiment. In the curative protocol, osteoclast numbers were higher than in the preventive and were not influenced by CT. Plasma Ca was 0.4 mM higher in the curative than in the preventive group.
The acute hypocalcemic effect measured 2 h after a single injection of CT was present both after 3 d and 6 d, 2 IU/rat of CT producing a decrease in plasma Ca of0.93 + 0.08 mM and 0.85±0.05 mM (mean±SEM, n = 3), respectively. These results suggest that osteoclasts recruited by the retinoid were sensitive to the hormone.
Discussion
Increased bone destruction has long been known to occur in vitamin A poisoning in animals and man (7) (8) (9) . Whereas it should be possible to use naturally occurring vitamin A or retinoic acid to stimulate bone resorption, we found both compounds to be impractical. Dosage of vitamin A is difficult because it goes to liver stores before hypervitaminosis A develops (21) , and retinoic acid produced necroses at the injection site when it was administered parenterally at the dose level required to induce hypercalcemia. Therefore, we used a new synthetic retinoid, one of the most potent retinoids currently available in terms of vitamin A activity (10, 1 1). Administration did not pose any problem.
The balance and 45Ca kinetics experiments as well as chemical analysis of the bones demonstrate that the retinoid stimulated bone resorption. This effect was likely to be due to a direct action on bone because vitamin A has been shown to stimulate bone resorption in organ culture in vitro (22) . In contrast, the changes in intestinal Ca absorption and in renal Ca excretion were probably indirect consequences of the increased Ca release from bone. Because plasma 1,25(OH)2D was decreased by retinoid given at large dose and because this vitamin D metabolite is considered to be the main stimulator of intestinal Ca absorption (23), the retinoid-induced decrease of the latter could be mainly explained by the decrease in plasma 1,25(OH)2D. The decrease in plasma 1,25(OH)2D could be due to a direct effect of the retinoid on the renal 25(OH)D-l-hydroxylase (24) . However (Fig. 2) . Therefore, an additional, possibly 1,25(OH)2D-independent effect of the retinoid on the intestine cannot be ruled out.
Our data provide no evidence for a renal effect of the retinoid on Ca metabolism. The retinoid-induced increase in urinary Ca is explained by an increase in filtered load as a consequence of hypercalcemia. Moreover, retinoid-induced hypercalcemia was completely prevented by C12MBP. This inhibitor of bone resorption has been shown not to influence the renal handling of Ca (26) , and therefore a renal contribution to the retinoid-induced hypercalcemia should have become apparent in Cl2MBP-treated animals.
It appears, therefore, that the retinoid influenced Ca metabolism by a primary action on bone resorption, which led to the observed changes in plasma Ca, 1,25(OH)2D, Ca absorp- Fig. 5 was found to be optimal with respect to the rapidity of the increase in plasma Ca vs. the appearance of general signs of hypervitaminosis A, which occurred only after hypercalcemia was established. The observed decrease in bone mass demonstrated the stimulatory effect of the retinoid on bone destruction under these experimental conditions. Moreover, the finding of an increase in the number of osteoclasts suggested that the increased bone resorption was mainly due to the generation of new osteoclasts rather than an activation of those present in bone. An increase of osteoclast numbers has previously been reported with vitamin A in vivo (7, 9) and in vitro (22) .
The effect of bisphosphonates on retinoid-induced hypercalcemia shows that plasma Ca is a reliable index for the effect of inhibitors of bone resorption in this model. These pharmacological agents have been shown to inhibit bone resorption specifically in vivo and in vitro (19) . The dose-related inhibition of retinoid-induced hypercalcemia agrees very well with histomorphometric data obtained with these three compounds (20) , the potencies of the bisphosphonates being identical with both methods. The compounds had similar potencies in preventing and reversing retinoid-induced hypercalcemia, showing that the sensitivity ofbone resorption to this type ofinhibitor was similar in both situations.
While the observed increase in the number of osteoclasts showed that recruitment of new osteoclasts was involved in retinoid-induced bone resorption, they did not indicate whether this occurred at the level of proliferation of osteoclast precursors or by an effect on the fusion of postmitotic precursors. To address this question and moreover to assess whether recruitment was also of importance in maintaining retinoidinduced bone resorption at a high level, the irradiation experiments were performed. The prevention of retinoid-induced hypercalcemia by irradiation suggests that proliferation of osteoclast precursors plays a major role in the stimulation of bone resorption. However, from the lack of effect of irradiation in reducing established hypercalcemia, it appears that proliferation of osteoclast precursors is not important in maintaining retinoid-induced bone resorption.
The results obtained with CT on retinoid-induced hypercalcemia are strikingly similar to those of the irradiation experiments, suggesting that this hormone inhibited the proliferation of osteoclast precursors. This conclusion is in agreement with reports in the literature which showed that CT inhibited the vitamin A-induced increase in osteoclast number in organ culture in vitro (22) . A decrease of osteoclast number with CT given for 4 wk was also observed in vivo in TPTX rats (27) . In the curative protocol, osteoclast numbers were higher than those in the preventive (Table IV) , suggesting that new osteoclasts may have been formed between day 3 and 6 in the curative protocol. CT did not affect this process. Because the experiments with irradiation show that proliferation played a minor role in maintaining bone resorption at a high level in the 3-d period of the curative protocol studied, an increase in osteoclast number in this period appears to be due to a postmitotic process unaffected by CT. The acute hypocalcemic effect of CT in the preventive and curative protocols confirms the well-known direct inhibitory action of CT on osteoclasts (28).
A comparison of the effects of CT with those of bisphosphonates on retinoid-induced hypercalcemia demonstrates that this model is suitable to distinguish between different mechanisms of action of inhibitors of bone resorption. Whereas CT appears to inhibit proliferation of osteoclast precursors, at least one of the actions of bisphosphonates is independent of this process. However, it remains to be established whether they act on recruitment as well. A histological investigation is required to answer this question.
In conclusion, we have shown that retinoid-induced bone resorption represents a new animal model to study the induction of this process in vivo. Because proliferation of osteoclast precursors appears to play a major role in this system, the model may be a valuable tool to study this process in vivo. To our knowledge, no comparable animal model has yet been described. Moreover, the study shows that retinoid-induced bone resorption is suitable to study the effects of inhibitors of bone resorption, and, moreover, to differentiate between effects on the activity of osteoclasts present and on proliferation of osteoclast precursors. Because much information can be obtained by monitoring plasma Ca, the model represents also an efficient system to test new inhibitors of bone resorption and may be of value in the development of new compounds.
